Novo Not Discussing Further Pill Discounts, CEO Says

Novo Nordisk CEO Mike Doustdar stated the company is not currently discussing additional discounts on its weight-loss medication Wegovy, according to Bloomberg. The statement came as Wegovy sales fell short of investor expectations. Doustdar made the comments during an interview with Bloomberg's Francine Lacqua.

Next story